Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
Go back to Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting| Actinium Pharmaceuticals, Inc. (NYSE: ATNM) | Delayed: 1.02 -0.01 (0.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.03 | 52 Week High | $3.50 | |||
| Open | $1.05 | 52 Week Low | $0.86 | |||
| Day High | $1.05 | P/E | N/A | |||
| Day Low | $1.01 | EPS | $-7.61 | |||
| Volume | 40,367 | |||||
